Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma†: Profile Report

Author： Croxtall Jamie D.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.5, 2011-10, pp. : 329-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†

By Keating Gillian M.  

BioDrugs, Vol. 25, Iss. 1, 2011-02 ,pp. : 55-61

Adis International

Access to resources Recommend Favorite

Rituximab: Current Status as Therapy for Malignant and Benign Hematologic Disorders

By Abdulla Nihal E.   Ninan Mary J.   Markowitz Avi B.  

BioDrugs, Vol. 26, Iss. 2, 2012-04 ,pp. : 71-82

Adis International

Access to resources Recommend Favorite

Rituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis

By  

Clinical Case Reports, Vol. 6, Iss. 2, 2018-02 ,pp. : 442-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer

By Simons W.R.   Jones D.   Buzdar A.  

Clinical Therapeutics, Vol. 25, Iss. 11, 2003-11 ,pp. : 2972-2987

Elsevier

Access to resources Recommend Favorite

Spotlight on Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

By Cvetković Risto S.   Perry Caroline M.  

BioDrugs, Vol. 20, Iss. 4, 2006-01 ,pp. : 253-257

Adis International

Access to resources Recommend Favorite